Data / Drug companies / Eli Lilly and Company
Eli Lilly and Company: 183 products in the FDA NDC directory, labeler code 0002
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Eli Lilly and Company (labeler code 0002) lists 183 products in the FDA National Drug Code Directory, covering 30 finished drugs by generic name. By type: 141 prescription drugs, 31 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 23, 2026.
The request: Watch Eli Lilly and Company (FDA labeler code 0002): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0002
- Products in commercial distribution
- 183
- Packages
- 226
- Finished drugs by generic name
- 30
- Prescription products
- 141
- Over the counter products
- 6
- Controlled substance products
- Schedule V 2
- Flagged as original packager
- 127 of 127 products that carry the flag
- Started marketing in the last 12 months
- 32
- Products with a marketing end date set
- 17
- Earliest marketing start
- October 28, 1982
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 89 | 48.6% |
| Biologics (BLA) | 57 | 31.1% |
| Drugs for further processing | 31 | 16.9% |
| Bulk ingredients | 5 | 2.7% |
| Emergency use authorization | 1 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 141 | 77% |
| Drugs for further processing | 31 | 16.9% |
| Over the counter drugs | 6 | 3.3% |
| Bulk ingredients | 5 | 2.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Tirzepatide | 48 | 2 |
| Insulin lispro | 13 | 4 |
| Insulin human | 7 | 4 |
| Mirikizumab-mrkz | 7 | 1 |
| Atomoxetine hydrochloride | 7 | 8 |
| Orforglipron | 6 | 1 |
| Selpercatinib | 6 | 1 |
| Insulin lispro-aabc | 6 | 2 |
| Ixekizumab | 4 | 1 |
| Baricitinib | 4 | 1 |
| Abemaciclib | 4 | 1 |
| Dulaglutide | 4 | 2 |
| Galcanezumab-gnlm | 3 | 1 |
| Tadalafil | 3 | 54 |
| Somatropin | 3 | 6 |
| Pirtobrutinib | 2 | 1 |
| Teriparatide | 2 | 7 |
| Ramucirumab | 2 | 1 |
| Insulin efsitora alfa-gobe | 2 | 1 |
| Lebrikizumab-lbkz | 2 | 1 |
| Pemetrexed disodium | 2 | 14 |
| Lasmiditan | 2 | 1 |
| Donanemab-azbt | 1 | 1 |
| Raloxifene hydrochloride | 1 | 16 |
| Diluent | 1 | 1 |
| Flortaucipir f-18 | 1 | 1 |
| Imlunestrant | 1 | 1 |
| Insulin glargine-aglr | 1 | 2 |
| Florbetapir f 18 | 1 | 1 |
| Insulin glargine | 1 | 5 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 116 | 63.4% |
| Injection, suspension | 15 | 8.2% |
| Tablet, film coated | 14 | 7.7% |
| Capsule | 9 | 4.9% |
| Tablet | 7 | 3.8% |
| Tablet, coated | 6 | 3.3% |
| Kit | 5 | 2.7% |
| Solution | 4 | 2.2% |
| Crystal | 4 | 2.2% |
| Injection, powder, lyophilized, for solution | 2 | 1.1% |
| Powder | 1 | 0.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| GLP-1 Receptor Agonist | 58 |
| Glucose-dependent Insulinotropic Polypeptide Receptor Agonist | 48 |
| Insulin Analog | 21 |
| Kinase Inhibitor | 12 |
| Insulin | 7 |
| Norepinephrine Reuptake Inhibitor | 7 |
| Interleukin-23 Antagonist | 5 |
| Interleukin-17A Antagonist | 4 |
| Janus Kinase Inhibitor | 4 |
| Phosphodiesterase 5 Inhibitor | 3 |
| Parathyroid Hormone Analog | 2 |
| Vascular Endothelial Growth Factor Receptor 2 Antagonist | 2 |
| Interleukin-13 Antagonist | 2 |
| Folate Analog Metabolic Inhibitor | 2 |
| Estrogen Agonist/Antagonist | 1 |
| Estrogen Receptor Antagonist | 1 |
| Radioactive Diagnostic Agent | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| ONSWIK KwikPen | 0002-5240 | Injection, solution | Biologics (BLA) | September 23, 2026 |
| ONSWIK KwikPen | 0002-5137 | Injection, solution | Biologics (BLA) | September 23, 2026 |
| Foundayo | 0002-4953 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Foundayo | 0002-4839 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Foundayo | 0002-4803 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Foundayo | 0002-4794 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Foundayo | 0002-4503 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Foundayo | 0002-4178 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Zepbound KwikPen | 0002-3566 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Zepbound KwikPen | 0002-3555 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Zepbound KwikPen | 0002-3544 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Zepbound KwikPen | 0002-3533 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Zepbound KwikPen | 0002-3522 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Zepbound KwikPen | 0002-3511 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Mounjaro KwikPen | 0002-3466 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Mounjaro KwikPen | 0002-3455 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Mounjaro KwikPen | 0002-3444 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Mounjaro KwikPen | 0002-3433 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Mounjaro KwikPen | 0002-3422 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Mounjaro KwikPen | 0002-3411 | Injection, solution | New drug applications (NDA) | January 20, 2026 |
| Zepbound | 0002-6612 | Injection, solution | New drug applications (NDA) | January 7, 2026 |
| Zepbound | 0002-6523 | Injection, solution | New drug applications (NDA) | January 7, 2026 |
| Zepbound | 0002-6304 | Injection, solution | New drug applications (NDA) | January 7, 2026 |
| Zepbound | 0002-6210 | Injection, solution | New drug applications (NDA) | January 7, 2026 |
| Zepbound | 0002-6103 | Injection, solution | New drug applications (NDA) | January 7, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.